Andreas H. Groll (Germany)

University Children's Hospital Muenster Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology
I am Professor of Paediatrics, Head of the Infectious Disease Research Programme and Deputy Director of the Department of Haematology/Oncology at the University Children's Hospital in Münster, Germany. My postgraduate education included fellowships in Infectious Diseases at the Children's Hospital in Boston, and in Paediatric Haematology/Oncology at the National Cancer Institute in Bethesda, Maryland. I am board certified in Paediatrics, Paediatric Haematology/Oncology, and Infectious Diseases. My research interests include infectious complications in the immunocompromised host, particularly invasive fungal infections, the pharmacokinetics and pharmacodynamics of antimicrobial agents, and the design and conduct of clinical research studies. I am a member of several international medical societies, on the editorial board of several international journals and have published more than 300 scientific articles thus far. I am regularly engaged in patient care as Attending Physician of the inpatient and outpatient service and the haematopoietic stem cell transplant program.

Author Of 2 Presentations

New Developments in Paediatric Antifungal Pharmacology

Date
Thu, 12.05.2022
Session Time
08:00 - 09:30
Session Type
Parallel Symposium
Room
MC 2 HALL
Lecture Time
08:02 - 08:27

ANTIFUNGAL USE IN EUROPEAN PEDIATRIC INTENSIVE CARE UNITS (PICUS): A 12-WEEK MULTICENTER MODIFIED POINT PREVALENCE STUDY (CALYPSO)

Date
Thu, 12.05.2022
Session Time
08:00 - 09:30
Session Type
Parallel Symposium
Room
MC 2 HALL
Lecture Time
09:07 - 09:17

Abstract

Backgrounds:

Knowledge of antifungal use in PICUs across Europe, while frequently prescribed, is limited. A 12-wk modified point-prevalence study was conducted to record antifungal use in Εuropean PICUs.

Methods

All patients hospitalized in the participating PICUs and receiving systemic antifungals were included. Information about ward demographics was collected once at the beginning; weekly ward and patient data were collected prospectively for the 12-wk study period and entered in REDCap database.

Results:

table 1.antifungal agents in picus.png

18 PICUs (15 hospitals), in 10 European countries participated. 8/18 (44%) of PICUs followed prophylactic practices for patients with immunocompromise/neutropenia, long-term parenteral nutrition or central lines, 7/18 (39%) had an antifungal stewardship program implemented and the majority (16/18) used biomarkers (15/16 galactomannan, 12/16 each beta-D-glucan and Cryptococcal antigen). 101 patients with ages ≤90d (14 patients), 3-60mo (44pts) and >5yrs (43pts) were recorded. Malignancy was the most common underlying condition among patients aged >90d (28%) followed by surgery/trauma (25%), whereas all patients ≤90d had previous surgery. Indication for antifungal prescribing was prophylaxis in 38% and treatment in 62% [empirical (57%), preemptive (13%) and targeted (30%)]. Fluconazole was the most common agent both for prophylaxis [45%, median dose: 6 (range 2-9) mg/kg/d] and empirical treatment [53%, median dose: 10 (range 1-12) mg/kg/d], whereas LAMB was the most frequent agent for targeted treatment [37%, median dose: 5 (range 3-6) mg/kg/d] (Table 1). Common reasons for empirical and targeted treatment were persistent fever in high-risk patients (58%) and candidiasis (100%), respectively. For targeted treatment, the most frequent pathogens were Candida albicans (37%) and Candida parapsilosis (32%).

Conclusions/Learning Points:

The majority of antifungal prescriptions across European PICUs were for prophylaxis or empirical treatment. These data will be valueable for guiding antifungal stewardship strategies in PICUs

Hide

Presenter of 1 Presentation

New Developments in Paediatric Antifungal Pharmacology

Date
Thu, 12.05.2022
Session Time
08:00 - 09:30
Session Type
Parallel Symposium
Room
MC 2 HALL
Lecture Time
08:02 - 08:27